TransIent Perivascular Inflammation of the Carotid Artery (TIPIC) Syndrome: Clinical and Radiological Follow-up (TIPIC-UNV)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- CHU de Montpellier
-
Paris, France, 75019
- Fondation Ophtalmologique A. De Rothschild
-
Paris, France, 75013
- Hôpital Pitié Salpetrière
-
Paris, France, 75014
- Centre Hospitalier de Saint-Anne
-
Toulouse, France, 31059
- CHU de Toulouse
-
Tours, France, 37044
- CHU de Tours
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with at least one episode of TIPIC syndrome for more than 12 months
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assess the incidence of recurrence of TIPIC syndrome after a first episode
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MOA_2018_2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasculitis
-
NCT01934504TerminatedANCA-Associated Vasculitis
-
NCT04737343RecruitingANCA Associated Vasculitis | Maintenance Therapy
-
NCT05416723Not yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental Exposure
-
NCT04973033CompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway Deregulation
-
NCT07151521RecruitingANCA-associated Vasculitis
-
NCT05962840Recruiting
-
NCT02994927CompletedA Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)ANCA-Associated Vasculitis
-
NCT07258524RecruitingANCA Associated Vasculitis (AAV)
Clinical Trials on Ultrasound exam with Doppler
-
NCT02678091Completed
-
NCT04583163TerminatedStroke | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Cerebral Aneurysm | Cerebral Ischemia | Vasospasm, Cerebral
-
NCT02917213CompletedMyocardial Infarction | Heart Diseases | Stroke | Thrombosis | Acute Disease
-
NCT06995222RecruitingRenal Replacement Therapy for Acute Kidney Injury in ICU | Akut Kidney Injury
-
NCT03505840UnknownAntiphospholipid Syndrome in Pregnancy
-
NCT06164015Not yet recruitingRecurrent Miscarriage
-
NCT07205549Not yet recruitingMusculoskeletal Ultrasound | IBD (Inflammatory Bowel Disease)
-
NCT04314791CompletedPlacenta Accreta Spectrum
-
NCT06277687Completed